Hematopoietic cells |
Monocytes and macrophages |
LL-37 and β-defensins are monocyte chemoattractants in vitro and in vivo. LL-37 has anti-endotoxic activity, induces chemokine production, promotes IL-1β secretion, but inhibits inflammatory responses to certain TLR ligands |
32, 61, 62
|
Neutrophils |
LL-37 and defensins are produced by neutrophils, stored within neutrophil granules and play an important microbicidal role in phagolysosomes. When released extracellularly, LL-37 acts as a neutrophil chemoattractant, inhibits neutrophil apoptosis, reduces pro-inflammatory cytokines and promotes both chemokine induction and the antimicrobial functions of neutrophils |
63, 64
|
Mast cells |
Mast cells are important producers of LL-37 in the skin. LL-37 and β-defensins are mast cell chemoattractants and promote mast cell degranulation |
65, 66
|
Conventional dendritic cells |
Defensins and cathelicidins are dendritic cell (DC) chemoattractants. LL-37 promotes differentiation of monocyte-derived DCs, but inhibits DC maturation and activation by TLR-ligands. β-Defensin 2 might promote DC activation as an endogenous TLR4 ligand. The adjuvant activities of defensins and cathelicidins in vivo might be mediated in part through their activity on DCs |
67, 68, 69
|
Plasmacytoid dendritic cells |
LL-37 in complex with DNA oligonucleotides strongly induces IFNα production by plasmacytoid DCs. This activity might contribute to the pathology of psoriasis |
[70] |
Epithelial cells |
Keratinocytes |
LL-37 promotes keratinocyte migration and production of IL-8, inhibits keratinocyte apoptosis, modulates responses to TLR ligands, and might have wound healing activities in the skin. Altered proteolytic processing of hCAP18 and LL-37 has been implicated in the pathology of rosacea |
54, 71, 72
|
Bronchial epithelium |
LL-37 acts on bronchial epithelial cells to stimulate cytokine and chemokine production and promote apoptosis |
73, 74
|
Intestinal epithelium |
α-Defensins are produced by Paneth cells and their microbiocidal activity plays an important role in the immune defenses of the gut. Reduced α-defensin production might contribute to Crohn's disease. LL-37 promotes mucin production and survival of intestinal epithelial cells |
75, 76
|
Other cells |
Vascular endothelium |
LL-37 induces activation and proliferation of vascular endothelium, promoting angiogenesis |
[77] |
Mesenchymal stromal cells |
LL-37 acts as a chemokine for mesenchymal stromal cells and promotes the production of various cytokines, as well as VEGF and MMP2; this can contribute to angiogenesis and tumor progression |
[57] |
Cancer cells |
LL-37 promotes migration and proliferation of lung, ovarian and breast cancer cells and LL-37 production by cancer cells in vivo promotes tumor growth. However, LL-37 also augments the anti-cancer therapeutic activity of CpG oligonucleotides |
78, 79
|